Successful treatment of multiply relapsed lymphoma with rituximab as a single agent.
The treatment of non-Hodgkin lymphoma (NHL) is an example of the successful therapy of cancer in children; the cure rate overall at approximately 80%. Unfortunately, relapsed NHL has a dismal prognosis, and the customary treatment is highly toxic chemotherapy followed by hematopoietic stem cell transplantation (HSCT). A child with relapsed T-cell rich B-NHL was treated with rituximab alone. This was delivered in eight doses after the recurrence of disease after high-dose chemotherapy and allogenic HSCT that was undertaken for the first relapse. Eight years after the last dose of rituximab he remains in complete remission.